Progress in Neurotherapeutics and Neuropsychopharmacology

Table of Contents - 2007 - Volume 2, Issue 01  


Review Article

Clinical Trials in Dementia

Encarnita Raya-Ampil a1 and Jeffrey L. Cummings a2c1
a1 Department of Neurology and Psychiatry, University of Santo Tomas, Manila, Philippines; Email: kanlaon200@yahoo.com
a2 Departments of Neurology and Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Email: jcummings@mednet.ucla.edu

Article author query
raya-ampil e   [PubMed][Google Scholar] 
cummings jl   [PubMed][Google Scholar] 

ABSTRACT

Dementia, particularly Alzheimer's disease (AD), is increasing by patient population included in clinical trials. The methodology for trials of AD patients have been defined in terms of outcomes, standard measures and analytic techniques. Trial methodology is evolving with experience as new potential therapies become available. Screening criteria, instrumentation choices, duration of trials and analytic strategies may have a profound impact on the conclusions that can be derived from trials. The components of AD trials are reviewed in detail in this chapter.


Correspondence:
c1 Correspondence should be addressed to: Jeffrey L. Cummings, MD, Departments of Neurology and Psychiatry and Biobehavioral Sciences, Reed Neurological Research Center, David Geffen School of Medicine at UCLA, 710 Westwood Plaza, Suite 2-238, P.O. Box No. 951769, Los Angeles, CA 90095-1769, USA; Tel: 310 206 5239; Fax: 310 206 5287; Email: jcummings@mednet.ucla.edu